Profile data is unavailable for this security.
About the company
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
- Revenue in USD (TTM)50.04m
- Net income in USD-59.86m
- Incorporated2020
- Employees99.00
- LocationInvivyd Inc209 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (781) 819-0080
- Fax+1 (302) 655-5049
- Websitehttps://invivyd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology Inc | 228.37m | 31.11m | 315.94m | 179.00 | 10.17 | 2.40 | 7.51 | 1.38 | 0.6104 | 0.6104 | 4.51 | 2.59 | 1.06 | 8.17 | 5.33 | 1,275,816.00 | 14.48 | 4.80 | 24.66 | 8.38 | 74.53 | 74.14 | 13.62 | 4.58 | 1.93 | 14.66 | 0.1473 | 0.00 | -0.9099 | 0.2881 | 2.75 | -- | -67.65 | -- |
| Akebia Therapeutics Inc | 236.20m | -5.35m | 326.81m | 194.00 | -- | 9.93 | -- | 1.38 | -0.0179 | -0.0179 | 0.8976 | 0.1229 | 0.791 | 2.55 | 5.80 | 1,217,505.00 | -1.79 | -27.07 | -3.03 | -45.24 | 82.83 | 78.83 | -2.26 | -45.92 | 1.46 | 1.07 | 0.8558 | -- | 47.46 | -4.33 | 92.30 | -- | 91.19 | -- |
| Elite Pharmaceuticals Inc | 140.12m | 43.41m | 414.11m | 68.00 | 9.94 | 5.14 | 9.20 | 2.96 | 0.0387 | 0.0387 | 0.1268 | 0.0748 | 1.29 | 3.03 | 4.18 | 2,060,564.00 | 39.98 | 13.18 | 45.86 | 16.01 | 51.06 | 47.19 | 30.98 | 13.97 | 5.44 | -- | 0.0517 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 427.16m | 120.00 | -- | 3.37 | -- | 6.38 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 445.42m | 46.00 | 6.01 | 2.19 | 5.93 | 2.59 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Invivyd Inc | 50.04m | -59.86m | 456.82m | 99.00 | -- | 3.73 | -- | 9.13 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 461.80m | 900.00 | 6.89 | 0.807 | 2.65 | 0.5854 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 467.97m | 31.00 | -- | 20.24 | -- | 6.66 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 501.61m | 59.00 | 15.08 | 3.76 | 12.34 | 5.94 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 502.65m | 142.00 | -- | -- | -- | 11.58 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| CorMedix Inc | 214.30m | 162.50m | 544.43m | 64.00 | 3.37 | 1.45 | 3.26 | 2.54 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Ironwood Pharmaceuticals, Inc. | 296.15m | 24.02m | 593.53m | 100.00 | 33.76 | -- | 22.92 | 2.00 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 599.36m | 162.00 | 5.35 | 5.09 | 5.18 | 2.12 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
Data as of Mar 04 2026. Currency figures normalised to Invivyd Inc's reporting currency: US Dollar USD
79.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 32.54m | 15.55% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 21.79m | 10.41% |
| BVF Partners LPas of 31 Dec 2025 | 19.53m | 9.33% |
| Maverick Capital Ltd.as of 31 Dec 2025 | 18.97m | 9.07% |
| RA Capital Management LPas of 31 Dec 2025 | 17.12m | 8.18% |
| Point72 Asset Management LPas of 31 Dec 2025 | 16.65m | 7.96% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 13.06m | 6.24% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.54m | 4.56% |
| M28 Capital Management LPas of 31 Dec 2025 | 9.25m | 4.42% |
| Saturn V Capital Management LPas of 31 Dec 2025 | 7.74m | 3.70% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
